Could Children Hold the Key to an HIV Cure?

Goulder has long been intrigued by the possibility that children might be pivotal in finding a breakthrough in the battle against HIV.

Beginning in the mid-2010s, this pediatrician and immunologist from the University of Oxford collaborated with researchers in South Africa's KwaZulu-Natal to study hundreds of children who contracted HIV from their mothers during pregnancy, delivery, or breastfeeding.

After integrating antiretroviral medications into these children's early treatment plans, Gondler and his team closely observed their adherence and responsiveness. Despite their expectations, some children unexpectedly stopped visiting the clinic for medications. Months later, when they were relocated, they displayed no symptoms of HIV, with undetectable viral levels.

“Their viral loads weren't just low; they couldn't be measured at all,” Goulder stated, pointing out how unusual this was since HIV usually resurfaces in a few weeks without treatment.

Intriguingly, these five children continued to show remission even after significant periods without medication. Could the outcome of HIV research lie in pediatric cases rather than adults?

Conference Insights from Rwanda

At a recent AIDS conference in Kigali, Alfredo Tagarro from Infanta Sofia University Hospital shared findings that up to 5% of HIV-positive infants receiving early antiretroviral treatment can suppress the virus extensively. “It's probable we'll see a successful HIV treatment emerge for children before adults due to their unique immune characteristics,” Tagarro mentioned.

Mark Cotton of the University of Stellenbosch supported this view, indicating children as optimal candidates for a cure. He highlighted their resilient and flexible immune systems as critical factors.

Progress and Challenges in Pediatric HIV Research

Although some adults have achieved remission from HIV following stem cell procedures primarily for cancer treatment, these methods aren't viable for all due to potential risks. Instead, some children have shown potential for suppressing HIV on their own after initial antiretroviral therapy.

This potential was first hinted at by isolated cases, such as the 'Mississippi baby' and a South African child who managed to keep the virus at bay longer than typical post-treatment durations.

Understanding the Unique Pediatric Response

Goulder has embarked on a study involving 19 South African children to unravel the mechanisms behind such extensive virus control post-treatment. Early results indicate that six children maintained virus suppression without drugs exceeding 18 months. A gender-based analysis hints that boys, perhaps due to biological nuances, have a better innate response to HIV.

Girls' innate immune responses are naturally more aggressive, which paradoxically enhances vulnerability since HIV targets active immune cells. Additionally, HIV strains in girls often resist innate defenses due to shared maternal immunity.

Advancing Therapeutics and Immune Enhancements

Developments in therapies such as broadly neutralizing antibodies (bNAbs) offer promise by targeting diverse HIV strains and attempting to eradicate dormant virus strains. Potential therapeutic vaccines are being developed to fortify children's immune systems specifically against HIV.

New trials are poised to test combinations of existing treatments with innovative bNAbs, seeking better long-term suppression or elimination of HIV in pediatric cases.

Exploring Gene Therapy

Children might benefit immensely from a possible one-time gene therapy, especially in regions where keeping up with ongoing medications is challenging. This approach instructs the body to consistently produce bNAbs, offering a sustainable solution.

Maurico Martins is leading this exploration and sees feasibility in delivering therapy shortly after birth to preemptively mitigate virus transmission, particularly in high-prevalence areas.

Future Perspectives and Challenges

While HIV in children remains a smaller subset within overall infections, understanding it may present broader treatment avenues. Current funding challenges exist, but potential partnerships could pave the way for significant advancements.

“We can garner valuable insights from children,

Goulder concludes, highlighting the distinctive path pediatric cases could provide towards treating HIV universally.